In this article, we will discuss: 10 Best Brain-Computer Interface Stocks to Buy.
On May 10, Bloomberg reported that brain-computer interfaces are transitioning from experimental to early implementation, allowing users to control computers, robotic arms, and communication tools with neural signals. Researchers have developed implanted and non-invasive devices that translate brain activity into commands, helping patients with paralysis and neurological disorders to regain function. Based on the report, just a few hundred people have received implants due to limited regulatory permissions, but developments in artificial intelligence and hardware are speeding up progress and moving the industry toward an inflection point.
According to Bloomberg, investment momentum is rising in the area, with Elon Musk and Sam Altman backing it. Elon Musk’s Neuralink has implanted devices in over 20 patients and plans to scale to 20,000 per year by 2031, whereas Synchron has tested devices in approximately 10 patients. Bloomberg data showed US BCI funding touched $2.75 billion, while China’s sector surpassed 1.8 billion yuan in 2025, showing rising global investment and competition.
With that said, here are the 10 Best Brain-Computer Interface Stocks to Buy.
Methodology:
We used screeners to identify Best Brain-Computer Interface Stocks and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds. We then identified those with the highest number of hedge fund holders, which we assessed using Insider Monkey’s database of hedge funds as of Q1 2026. The stocks are ranked in ascending order of the number of hedge fund holders.
Note: This list includes both pure-play BCI developers and supporting infrastructure businesses.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. CeriBell, Inc. (NASDAQ:CBLL)
Number of Hedge Fund Holders: 15
CeriBell, Inc. (NASDAQ:CBLL) is among the Best Brain-Computer Interface Stocks.
On June 8, CeriBell, Inc. (NASDAQ:CBLL) reported a study published in Critical Care Medicine that higher AI-detected seizure burden is linked with increased odds of disability results at discharge. It analyzed 359 adult patients across three academic centers.
The company said patients with a peak seizure burden of at least 90% were 3.4 times more likely to experience death or severe disability compared to those with no seizure burden. Hence, the elevated burden directly leads to poorer functional outcomes.
The medtech firm revealed that risk develops with time. It stated that each additional hour of AI-detected seizure activity nearly doubled the odds of severe disability or death, noting an adjusted odds ratio of 1.98.
Lead author Josef Parvizi said the algorithm detects clinically relevant biomarkers with prognosis, underlining potential for earlier intervention.
CEO Jane Chao said continuous monitoring allows live assessment and more informed clinical decisions.
CeriBell, Inc. (NASDAQ:CBLL) is a commercial-stage medical technology firm that works to transform the diagnosis and treatment of patients with severe neurological conditions.
9. NeuroPace, Inc. (NASDAQ:NPCE)
Number of Hedge Fund Holders: 23
On May 29, NeuroPace, Inc. (NASDAQ:NPCE) said it received U.S. Food and Drug Administration approval for ECoG Assistant, the first “AI-driven clinician-enabled feature.” It is designed to help epilepsy care using long-term intracranial EEG data.
Built on 124,450 epileptologist-labeled records, the company reported that the tool has “ECoGs of Interest.” It allows physicians to review trends and timing patterns across months through integrated reports and charts, improving efficiency in data review and treatment decisions.
Chief Medical Officer Martha Morrell said the feature “represents an important advancement,” with faster access to insights for more informed care.
CEO Joel Becker said the approval shows how the firm’s data advantage is moving toward “practical tools for clinicians.”
NeuroPace, Inc. (NASDAQ:NPCE) debuted the technology at the ASSFN Annual Meeting on May 30. It has submitted its next-generation patient data platform for FDA review, targeting approval in the second quarter of 2026.
NeuroPace, Inc. (NASDAQ:NPCE) creates, produces, and markets implantable devices to treat epilepsy and neurological illnesses. It offers implantable components such as the RNS neurostimulator and depth and cortical strip leads.
